Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD
Add to favourite- Summary
- Historical Data
| Spread | 21.9 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.012355% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.009867% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | JPY | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Japan | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8245.7 |
| Open | 8124.4 |
| 1-Year Change | 57.71% |
| Day's Range | 8056.2 - 8366.8 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 8260.2 | 140.3 | 1.73% | 8119.9 | 8265.4 | 8056.2 |
| Apr 23, 2025 | 8245.7 | -0.3 | -0.00% | 8246.0 | 8313.5 | 8101.6 |
| Apr 22, 2025 | 8310.4 | -13.6 | -0.16% | 8324.0 | 8337.1 | 8210.9 |
| Apr 21, 2025 | 8440.7 | 215.8 | 2.62% | 8224.9 | 8449.6 | 8199.6 |
| Apr 18, 2025 | 8344.7 | 84.7 | 1.03% | 8260.0 | 8413.7 | 8231.3 |
| Apr 17, 2025 | 7053.8 | 238.6 | 3.50% | 6815.2 | 7075.3 | 6797.3 |
| Apr 16, 2025 | 6725.3 | 48.9 | 0.73% | 6676.4 | 6740.3 | 6630.0 |
| Apr 15, 2025 | 6611.7 | -52.7 | -0.79% | 6664.4 | 6743.3 | 6598.2 |
| Apr 14, 2025 | 6586.4 | 215.7 | 3.39% | 6370.7 | 6688.5 | 6343.2 |
| Apr 11, 2025 | 6282.7 | -107.9 | -1.69% | 6390.6 | 6396.5 | 6223.4 |
| Apr 10, 2025 | 6709.8 | -19.3 | -0.29% | 6729.1 | 6790.2 | 6620.6 |
| Apr 9, 2025 | 6346.6 | -102.0 | -1.58% | 6448.6 | 6499.6 | 6282.5 |
| Apr 8, 2025 | 6513.5 | -52.2 | -0.80% | 6565.7 | 6617.4 | 6416.2 |
| Apr 7, 2025 | 6364.7 | -188.8 | -2.88% | 6553.5 | 6627.4 | 6263.8 |
| Apr 4, 2025 | 6651.4 | 38.0 | 0.57% | 6613.4 | 6916.1 | 6555.0 |
| Apr 3, 2025 | 6626.1 | 224.5 | 3.51% | 6401.6 | 6670.2 | 6381.6 |
| Apr 2, 2025 | 6554.4 | -161.9 | -2.41% | 6716.3 | 6743.6 | 6539.0 |
| Apr 1, 2025 | 6753.4 | -57.8 | -0.85% | 6811.2 | 6878.3 | 6744.2 |
| Mar 31, 2025 | 6793.4 | -15.8 | -0.23% | 6809.2 | 6856.6 | 6735.7 |
| Mar 28, 2025 | 6998.7 | 6.4 | 0.09% | 6992.3 | 7016.3 | 6932.4 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Chugai Pharmaceutical Co., Ltd. Company profile
About Chugai Pharmaceutical Co Ltd
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chugai Pharmaceutical Co Ltd revenues increased 27% to Y999.76B. Net income increased 41% to Y303B. Revenues reflect Net Sales increase of 27% to Y802.84B, Royalties and other operating revenues increase of 28% to Y196.92B. Dividend per share increased from Y55.00 to Y76.00. Basic Earnings per Share excluding Extraordinary Items increased from Y130.66 to Y184.29.
Equity composition
FY'03, the Co. changed FY end from March to December. FY'94-'02 WAS & FY'04 Q1 &Q3 WAs & O/S were estimated. 3/05 & 9/05, WAS, O/S, DPS were estimated. FY'06 Q3 & '07 Q1, Q3 WAS& DWAS were estimated, and its WAS was used as O/S. FY'08 1Q WAS & DWAS were estimated and WAS was used as o/s. FY'08 Q3 WAS estimated and used as o/s.
| Industry: | Pharmaceuticals (NEC) |
日本橋三井タワー15f
日本橋室町2-1-1
CHUO-KU
TOKYO-TO 103-8324
JP
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com